

CONTINUED ON NEXT PAGE

Some analyte-specific reagents used in these in-house procedures are classified under Class I devices by the FDA and are exempt from the premarket notification requirements of Section 510(k) of the Act. This test was developed and its performance characteristics were determined by Immunoscience Lab, Inc. It does not have to be cleared by the FDA, pursuant to Act 21 CFR 809.30(e). These tests have undergone stringent quality control and assurance, and comparison studies have been performed in compliance with the State of California's requirements.

te's Syndrome. Psychiatry Research 101:107, 2001.
4-Vojdani A. et al. Antibodies to Neuron-specific Antigens in Children with Autism: Possible Cross-reaction with Encephalitic Proteins from Milk, Chlamydia pneumoniae and Streptococcal Group A. J. Neuroimmunology 129:169, 2002.
5-Perlmutter SJ et al. Therapeutic Plasma Exchange and IVIG for Obsessive Compulsive Disorder and TIC Disorders in Childhood. Lancet 354:1153, 1999.

TEST	RESULTS	REFERENCE RANGE	UNITS
------	---------	-----------------	-------

JAQUELYN MCCANDLESS, M.D. P.O. BOX 1066 HONOLULU, HI. 96727			
Blood Drawn	Processed	Reported	ISL No.
07/18/06	07/20/06	08/03/06	200714

REFERRING PHYSICIAN

Patient Name: PARK-ALVAREZ, RUBEN
Patient I.D.: DUB00062002

Immunoscience Lab, Inc.
Rahim Karjoo, M.D. Medical Director



23